Your session is about to expire
← Back to Search
Cervical Dilator Device
Aqueduct 100 dilation for Cervical Dilation
N/A
Waitlist Available
Led By Larry Spiegelman, Dr.
Research Sponsored by Aqueduct Medical Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 11 months
Awards & highlights
Study Summary
Evaluation of efficacy and safety of using Aqueduct -100 - Cervical Dilator Device, focusing on diagnostic or operative hysteroscopies.
Eligible Conditions
- Cervical Dilation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 11 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 11 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Occurrence of Adverse Events
Percentage of patients in which, through 1 minute dilation with Aqueduct-100, a cervix dilation of 5mm, required for diagnostic/ operative hysteroscopy, is reached.
Secondary outcome measures
Measurement of physicians'overall satisfaction with the device, through a questionnaire
Trial Design
1Treatment groups
Experimental Treatment
Group I: Aqueduct 100 dilationExperimental Treatment1 Intervention
Uterine cervix dilation through Aqueduct-100 device
Find a Location
Who is running the clinical trial?
Aqueduct Medical LtdLead Sponsor
2 Previous Clinical Trials
91 Total Patients Enrolled
Larry Spiegelman, Dr.Principal InvestigatorBaptist Medical Arts Surgical Center
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger